Traxion Sab De Cv Ord Shs GRPOF

At last fair analysis for Tetra. Taking knowledge

[Tameraq2]

I like this analysis for Tetra. Those ppl understand that the numbers do not apply to TBP because the assets of Tetra are mostly knowledge which is intangible value. This is what they say about tetra on cedarvillenews. In trying to determine the current valuation of Tetra Bio-Pharma Inc. (TSXV:TBP) shares, we note that the Book to Market ratio of the shares stands at 0.205422. Its commonly accepted that a Book to Market ratio greater than one indicates that the shares might be undervalued. The book to market ratio has some limitations in certain industries however where intangible assets (such as knowledge) often are not represented on a balance sheet. The ratio is calculated by dividing the market price per share by book value per share

[frobin2]

I thought the shares were undervalued already. So you're saying they're overvalued, or its harder to detemine due to the large amount of I/Ts on the Balance sheet?

[Tameraq2]

Book to Market ratio analysis doesn't apply to all industries. Pharma firms like TBP have knowledge that will produce revenue in the near future. So they don't have physical facilities like greenhouses that you can evaluate. You can't evaluate knowledge and you might spend more money to find the perfect strain for a certain pipeline than building a 5 acres green house. Knowledge is

[LeafRider]

This post has been removed in accordance with Community Policy

[Hammertown87]

Canopy Growth Strengthens Commitment to Cannabis-Based Medicines Through Completion of Canopy Health Innovations Acquisition THEY WILL TAKE A RUN AT US I THINK.$$$$$

[PCR1917]

I thought of it too. I think it is really a possibility when we look at how canopy health is talking about the importance of clinical trials. We also have a partner in common with neptune. Also, some people on canopy advisory board (dr mark ware) seems to be very close to some tetra's partners (people at sant cannabis and mcgill university). At least, if canopy is not interested in tbp, the

[LeafRider]

This post has been removed in accordance with Community Policy

[LeafRider]

This post has been removed in accordance with Community Policy

[frobin2]

It would only make sense to buy TBP than to venture on their own, especially with TBP so far ahead of the competition as far as trials, having a great relationship with FDA and Health Canada, and their arrangement with the major distributor not named yet, would only make Canopy's life a lot easier.  Now - this is a hypothetical situation and TBP senses that a buy out offer is on the

[LeafRider]

This post has been removed in accordance with Community Policy

[PCR1917]

I would answer you by a question: who has more money to manipulate the share price, a little biopharma like tbp to have a higher offer or a larger player (pharma or big lp) to pay a lower price?

[frobin2]

Thank you for the correction - I don't believe TBP is shorting the stock, I guess I meant large players. We'll have to keep an eye on who is purchasing/shorting/etc and speculate from there. So far in past week, we are starting to climb slowly little by little, so I'll just enjoy that for now.  Once phase 3 trial results are released, and the hopeful good news is out, there's